ABSK011 not checked

Abbisko Therapeutics Co, Ltd · ABSK-011 + atilizumab

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
5 active
6 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“ABSK-011 capsules will be provided and should be taken twice daily, with an interval of approximately 12 hours. The investigational product should be taken with food, with approximately 150 mL of water.”In the company’s words, NCT07327034 on ClinicalTrials.gov
Tested for
Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma, Advanced Liver Cancer
Main trialPhase 2
“This is a randomized, double-blind, multicenter, Phase 2 study to evaluate the efficacy and safety of ABSK-011 plus BSC versus placebo plus BSC in advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have received prior systemic therapy. Approximately 141 advanced or unresectable HCC patients with FGF19 overexpression who have received prior systemic therapy will be enrolled and randomized to experimental arm or control arm in a 2:1 ratio. Patients will receive assigned study treatment, every 28-day treatment cycle within 1 day of randomization until…”In the company’s words, NCT07327034 on ClinicalTrials.gov
Other names
ABSK-011 + atilizumab

Other drugs for Hepatocellular Carcinoma (HCC)

All 130 drugs for Hepatocellular Carcinoma (HCC)

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 Jun 2027 ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Phase 2Enrolling by invitation 31 Dec 2028 A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
Phase 1Not yet recruiting 7 Nov 2025 A Mass Balance Study of [14C]ABSK011
Phase 1Recruiting 10 Aug 2026 A Study to Evaluate the Effects of Low-Fat Meal, High-Fat Meal and Omeprazole Enteric-Coated Tablets on the Pharmacokinetics of ABSK-011 Capsules in Healthy Participants
Phase 1Recruiting 31 Dec 2027 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
Phase 1Completed 30 Sep 2025 A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ABSK011

Following is part of Solo: you see every change to ABSK011 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in